Published in Future Neurol on July 01, 2010
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21
Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLoS One (2014) 1.11
A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol (2013) 1.03
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag (2015) 0.84
Impact of genetic risk assessment on nutrition-related lifestyle behaviours. Proc Nutr Soc (2012) 0.81
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Disclosing individual genetic results to research participants. Am J Bioeth (2006) 22.12
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology (2007) 12.42
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
Forecasting the global burden of Alzheimer's disease. Alzheimers Dement (2007) 10.01
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Influence of education and occupation on the incidence of Alzheimer's disease. JAMA (1994) 8.43
Cognitive reserve. Neuropsychologia (2009) 8.41
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med (2001) 7.85
The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA (1998) 7.81
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med (2006) 7.14
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 6.53
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
Simple tools for understanding risks: from innumeracy to insight. BMJ (2003) 6.08
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol (2004) 5.78
Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol (2002) 5.69
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol (2009) 4.96
Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol (2010) 4.78
Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A (2006) 4.56
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
An agenda for personalized medicine. Nature (2009) 4.14
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making (2007) 3.74
Informing study participants of research results: an ethical imperative. IRB (2003) 3.65
Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology (2003) 3.60
2009 Alzheimer's disease facts and figures. Alzheimers Dement (2009) 3.45
Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology (1995) 3.37
The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil (2004) 3.37
ASHG Statement* on direct-to-consumer genetic testing in the United States. Obstet Gynecol (2007) 3.19
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet (1999) 3.14
Genomic profiles for disease risk: predictive or premature? JAMA (2008) 3.07
A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med (2008) 3.06
The incidence of dementia: a meta-analysis. Neurology (1998) 3.06
Predicting risk of dementia in older adults: The late-life dementia risk index. Neurology (2009) 2.92
The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry (1998) 2.91
Apolipoprotein E genotyping in Alzheimer's disease. National Institute on Aging/Alzheimer's Association Working Group. Lancet (1996) 2.87
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med (2005) 2.78
The new genetics. Psychological responses to genetic testing. BMJ (1998) 2.71
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J (2009) 2.66
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology (2007) 2.65
Genetic risk and behavioural change. BMJ (2001) 2.64
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology (2004) 2.63
Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol (1998) 2.53
Uptake of presymptomatic predictive testing for Huntington's disease. Lancet (1989) 2.49
The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA (1997) 2.45
Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial. Genet Med (2004) 2.44
Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet (1992) 2.39
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Promising strategies for the prevention of dementia. Arch Neurol (2009) 2.14
A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet (1999) 2.12
Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatry (2009) 2.08
Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons. Arch Neurol (1997) 2.07
APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet (1998) 2.05
What length of hospice use maximizes reduction in medical expenditures near death in the US Medicare program? Soc Sci Med (2007) 2.04
Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol (2005) 2.03
Physical exercise, aging, and mild cognitive impairment: a population-based study. Arch Neurol (2010) 2.02
Genetics of Alzheimer's disease: a centennial review. Neurol Clin (2007) 1.93
Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) (2005) 1.93
Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology (1996) 1.85
Mixed dementia: emerging concepts and therapeutic implications. JAMA (2004) 1.82
Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord (2003) 1.79
Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics (2007) 1.78
Predictive testing for Huntington's disease: the calm after the storm. Lancet (2000) 1.76
Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A (2004) 1.72
Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. Psychiatr Serv (2006) 1.54
Genomic medicine: who will practice it? A call to open arms. Am J Med Genet (2001) 1.47
How can we help people make sense of medical data? Eff Clin Pract (1999) 1.45
Systematic review of health behavioral risks and cognitive health in older adults. Int Psychogeriatr (2009) 1.44
Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. Neurology (2009) 1.41
Impact of APOE in mild cognitive impairment. Neurology (2004) 1.37
Public attitudes about genetic testing for Alzheimer's disease. Health Aff (Millwood) (2001) 1.34
Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist (2000) 1.33
Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment. J Am Geriatr Soc (2008) 1.31
Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol (2009) 1.30
Social engagement and cognitive function in old age. Exp Aging Res (2009) 1.29
The Genetic Information Nondiscrimination Act--a half-step toward risk sharing. N Engl J Med (2008) 1.26
Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev (2009) 1.25
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg (2005) 1.25
Psychological impact of genetic testing for Huntington's disease: an update of the literature. J Neurol Neurosurg Psychiatry (2000) 1.24
Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. Proc Natl Acad Sci U S A (2008) 1.23
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag (2015) 0.84